Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder

Reiji Yoshimura, Asuka Katsuki, Kiyokazu Atake, Hikaru Hori, Ryohei Igata, Yuki KonishiDepartment of Psychiatry, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan Objectives: The etiology of depression remains unknown. There is, however, a growing body o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yoshimura R, Katsuki A, Atake K, Hori H, Igata R, Konishi Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Fluvoxamine interleukin-6 plasma major depressive disorder Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/dc8c03dddd934c0cb294c6b809f6200e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dc8c03dddd934c0cb294c6b809f6200e
record_format	dspace
spelling	oai:doaj.org-article:dc8c03dddd934c0cb294c6b809f6200e2021-12-02T01:03:03ZInfluence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder1178-2021https://doaj.org/article/dc8c03dddd934c0cb294c6b809f6200e2017-02-01T00:00:00Zhttps://www.dovepress.com/influence-of-fluvoxamine-on-plasma-interleukin-6-or-clinical-improveme-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Reiji Yoshimura, Asuka Katsuki, Kiyokazu Atake, Hikaru Hori, Ryohei Igata, Yuki KonishiDepartment of Psychiatry, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan Objectives: The etiology of depression remains unknown. There is, however, a growing body of evidence that cytokines are involved in the pathophysiology of depression. The aim of this study is to investigate the effects of fluvoxamine on plasma interleukin-6 (IL-6) levels and on clinical improvement of the depressive state.Subjects and methods: Thirty patients who met the DSM-IV criteria for major depressive disorder (MDD) were enrolled in the study. Thirteen were male and 17 were female, and their ages ranged from 26 to 70 years (mean ± standard deviation 45.0±14.2). The patients were treated with fluvoxamine for 8 weeks. The dosages of fluvoxamine varied among the patients and, based on ethical considerations, were not fixed.Results: The fluvoxamine doses were positively related to plasma fluvoxamine levels (r=0.8798, P<0.001). A significant correlation was observed between the patients’ plasma IL-6 levels and their 17-item Hamilton Rating Scale for Depression (HAMD17) scores (r=0.4555, P=0.0010). A positive correlation was found between the delta plasma IL-6 (week 0–week 8) and the delta HAMD17 (week 0–week 8) (r=0.5226, P=0.002).Conclusion: Effect of fluvoxamine on IL-6 is partially associated with its clinical efficacy for MDD. Keywords: fluvoxamine, interleukin, Hamilton Rating Scale for Depression, major depressive disorderYoshimura RKatsuki AAtake KHori HIgata RKonishi YDove Medical PressarticleFluvoxamineinterleukin-6plasmamajor depressive disorderNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 13, Pp 437-441 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Fluvoxamine interleukin-6 plasma major depressive disorder Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Fluvoxamine interleukin-6 plasma major depressive disorder Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Yoshimura R Katsuki A Atake K Hori H Igata R Konishi Y Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
description	Reiji Yoshimura, Asuka Katsuki, Kiyokazu Atake, Hikaru Hori, Ryohei Igata, Yuki KonishiDepartment of Psychiatry, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Fukuoka, Japan Objectives: The etiology of depression remains unknown. There is, however, a growing body of evidence that cytokines are involved in the pathophysiology of depression. The aim of this study is to investigate the effects of fluvoxamine on plasma interleukin-6 (IL-6) levels and on clinical improvement of the depressive state.Subjects and methods: Thirty patients who met the DSM-IV criteria for major depressive disorder (MDD) were enrolled in the study. Thirteen were male and 17 were female, and their ages ranged from 26 to 70 years (mean ± standard deviation 45.0±14.2). The patients were treated with fluvoxamine for 8 weeks. The dosages of fluvoxamine varied among the patients and, based on ethical considerations, were not fixed.Results: The fluvoxamine doses were positively related to plasma fluvoxamine levels (r=0.8798, P<0.001). A significant correlation was observed between the patients’ plasma IL-6 levels and their 17-item Hamilton Rating Scale for Depression (HAMD17) scores (r=0.4555, P=0.0010). A positive correlation was found between the delta plasma IL-6 (week 0–week 8) and the delta HAMD17 (week 0–week 8) (r=0.5226, P=0.002).Conclusion: Effect of fluvoxamine on IL-6 is partially associated with its clinical efficacy for MDD. Keywords: fluvoxamine, interleukin, Hamilton Rating Scale for Depression, major depressive disorder
format	article
author	Yoshimura R Katsuki A Atake K Hori H Igata R Konishi Y
author_facet	Yoshimura R Katsuki A Atake K Hori H Igata R Konishi Y
author_sort	Yoshimura R
title	Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
title_short	Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
title_full	Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
title_fullStr	Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
title_full_unstemmed	Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
title_sort	influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/dc8c03dddd934c0cb294c6b809f6200e
work_keys_str_mv	AT yoshimurar influenceoffluvoxamineonplasmainterleukin6orclinicalimprovementinpatientswithmajordepressivedisorder AT katsukia influenceoffluvoxamineonplasmainterleukin6orclinicalimprovementinpatientswithmajordepressivedisorder AT atakek influenceoffluvoxamineonplasmainterleukin6orclinicalimprovementinpatientswithmajordepressivedisorder AT horih influenceoffluvoxamineonplasmainterleukin6orclinicalimprovementinpatientswithmajordepressivedisorder AT igatar influenceoffluvoxamineonplasmainterleukin6orclinicalimprovementinpatientswithmajordepressivedisorder AT konishiy influenceoffluvoxamineonplasmainterleukin6orclinicalimprovementinpatientswithmajordepressivedisorder
_version_	1718403348905852928

Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder

Ejemplares similares